Pint Pharma to facilitate expansion of Phase 3 INSPIRE trial to Argentina , Chile , and Brazil in preparation for future studies of oral rigosertib NEWTOWN, Pa. , Aug. 21, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on
NEWTOWN, Pa. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a Phase 3 stage biopharmaceutical company focused on developing rigosertib, a novel small molecule drug candidate to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided a
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday August 14, 2018 NEWTOWN, Pa. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat
New Role as the President involves leadership of the entire product portfolio Promotion reflects progress of Rigosertib to key data milestones NEWTOWN, Pa. , June 21, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering
NEWTOWN, Pa. , June 07, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced a presentation at the
LOS ANGELES, CA / ACCESSWIRE / May 29, 2018 / Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced
NEWTOWN, Pa. , May 15, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided a
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday May 15, 2018 NEWTOWN, Pa. , May 09, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer,
NEWTOWN, Pa. , May 03, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), announced that the Company will present
Underwriter’s Option to Purchase Additional Securities Exercised in Full NEWTOWN, Pa. , May 01, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to
NEWTOWN, Pa. , April 27, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX) (“Onconova” or “we”), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS),
Onconova receives productive pre-IND guidance from FDA regarding first-in-class compound ON 123300 Preclinical data reveals differential metabolism of ON 123300 in male versus female rodents, with implications for development of dosing strategy Development program is in collaboration with HanX
First presentation from dose exploration cohorts in an expanded trial addressing urinary safety of the novel combination therapy in higher risk patients with Myelodysplastic Syndromes (MDS) Study demonstrates elimination of grade 3 or grade 4 urinary adverse events after implementation of
NEWTOWN, Pa. , March 15, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), will present new data on ON 123300, a
NEWTOWN, Pa. , March 08, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided
